C12N 2760/18234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18234 (Use of virus or viral component as vaccine) appears on 29 US grants and 60 published applications in this corpus.
Search patents in C12N- Granted patents
- 29
- Published applications
- 60
- Assignees
- 34
- Inventors
- 115
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 2 |
| 2013 | 1 | 2 |
| 2014 | 1 | 1 |
| 2015 | 2 | 5 |
| 2016 | 1 | 3 |
| 2017 | 3 | 4 |
| 2018 | 4 | 1 |
| 2019 | 3 | 6 |
| 2020 | 2 | 2 |
| 2021 | 0 | 5 |
| 2022 | 4 | 3 |
| 2023 | 1 | 4 |
| 2024 | 1 | 4 |
| 2025 | 4 | 7 |
| 2026 | 1 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Paramyxovirus virus-like particles as protein delivery vehicles14 Apr 2026US 12,600,956 B2The Penn State Research Foundation
- Vaccines against Nipah virus, and methods of using same15 Jul 2025US 12,357,683 B2The Wistar Institute of Anatomy and Biology
- Paramyxovirus virus-like particles as protein delivery vehicles1 Apr 2025US 12,264,338 B2The Penn State Research Foundation
- Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors18 Mar 2025US 12,252,531 B2Scholar Rock, Inc.
- Henipavirus vaccine21 Jan 2025US 12,201,682 B2CureVac AG
- Engineered nipah virus mrna vaccine20 Aug 2026US 2026/0240981 A1Vernagen, LLC
- Methods for assembling protein-conjugated nanocarrier vaccines14 May 2026US 2026/0130982 A1Northwestern University
- Anti-Viral Therapeutic Peptides, Conjugates, and Methods of Use Thereof14 May 2026US 2026/0131011 A1Decoy Therapeutics Inc.
- Stabilized trimeric class i fusion proteins26 Mar 2026US 2026/0085096 A1Janssen Vaccines & Prevention B. V.
- Recombinant cedar virus chimeras21 Aug 2025US 2025/0263442 A1The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Most cited
By later US patents
- Zoonotic disease RNA vaccines40US 11,497,807 B2ModernaTX, Inc. · 2022
- Henipavirus vaccine9US 11,524,066 B2CureVac AG · 2022
- Nipah virus envelope pseudotyped lentiviruses and methods of their use7US 10,064,958 B2The Regents of the University of California · 2018
- Paramyxovirus virus-like particles as protein delivery vehicles6US 10,316,295 B2The Penn State Research Foundation · 2019
- Nipah virus envelope pseudotyped lentiviruses and methods of their use6US 11,576,982 B2The Regents of the University of California · 2023